# Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

> **NCT02775292** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Adult Solid Neoplasm
- Childhood Solid Neoplasm
- Metastatic Neoplasm

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
- **BIOLOGICAL:** NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT02775292
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-03
- **Primary completion:** 2019-04-08
- **Final completion:** 2019-04-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02775292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02775292, "Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02775292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*